Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
85.6M
-
Number of holders
-
101
-
Total 13F shares, excl. options
-
60.8M
-
Shares change
-
-2.6M
-
Total reported value, excl. options
-
$132M
-
Value change
-
-$12.3M
-
Put/Call ratio
-
0.73
-
Number of buys
-
46
-
Number of sells
-
-60
-
Price
-
$2.15
Significant Holders of Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share (LRMR) as of Q1 2025
138 filings reported holding LRMR - Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2025.
Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share (LRMR) has 101 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 60.8M shares
of 85.6M outstanding shares and own 71.03% of the company stock.
Largest 10 shareholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (21.2M shares), RA CAPITAL MANAGEMENT, L.P. (6.05M shares), JANUS HENDERSON GROUP PLC (5.57M shares), Blue Owl Capital Holdings LP (4.78M shares), BlackRock, Inc. (3.12M shares), GOLDMAN SACHS GROUP INC (2.67M shares), VANGUARD GROUP INC (2.22M shares), Opaleye Management Inc. (1.91M shares), Alyeska Investment Group, L.P. (1.44M shares), and RENAISSANCE TECHNOLOGIES LLC (975K shares).
This table shows the top 101 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.